In some cases, patients with the ultra-metabolizer variation of CYP2D6 could experience treatment failure and not be responding to medication while those with poor metabolizer could experience severe life-threatening reactions such as heart failure, cerebrovascular events, fatal respiratory depression, and even death [34,35]. This evidence concerns the gene CYP2D6 and heart failure.